UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 02, 2023 |
ENANTA PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware | 001-35839 | 04-3205099 | ||
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||
|
|
|
|
|
500 Arsenal Street |
| |||
Watertown, Massachusetts |
| 02472 | ||
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (617) 607-0800 |
Not applicable |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
| Trading |
|
|
Common Stock, par value $0.01 per share |
| ENTA |
| Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the annual meeting of stockholders held on March 2, 2023, Enanta’s stockholders voted on the following proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on January 20, 2023.
Proposal No. 1: To Elect Two Class I Directors to Serve Until the 2026 Annual Meeting of Stockholders or until their respective successors are elected and qualified.
The stockholders re-elected the following individuals as Class I directors of the Company:
Name of Director Nominee |
| Votes For |
|
| Votes Withheld |
|
| Broker Non-Votes |
| |||
Bruce L.A. Carter, Ph.D. |
|
| 14,297,051 |
|
|
| 3,316,218 |
|
|
| 1,371,281 |
|
Jay R. Luly, Ph.D. |
|
| 16,673,120 |
|
|
| 940,149 |
|
|
| 1,371,281 |
|
Proposal No. 2: To Approve, an Amendment to Our 2019 Equity Incentive Plan.
The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 975,000 shares.
Votes For |
|
| Votes Against |
|
| Abstain |
|
| Broker Non-Votes |
| ||||
| 10,921,099 |
|
|
| 6,676,871 |
|
|
| 15,299 |
|
|
| 1,371,281 |
|
Proposal No. 3: To Approve, on an Advisory Basis, the Compensation Paid to the Company’s Named Executive Officers.
The stockholders approved the advisory vote on executive compensation, referred to as a “say-on-pay” vote.
Votes For |
|
| Votes Against |
|
| Abstain |
|
| Broker Non-Votes |
| ||||
| 16,210,693 |
|
|
| 1,386,476 |
|
|
| 16,100 |
|
|
| 1,371,281 |
|
Proposal No. 4: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta’s Independent Registered Public Accounting Firm for the 2023 Fiscal Year.
The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2023.
Votes For |
|
| Votes Against |
|
| Abstain |
|
| Broker Non-Votes | |||
| 18,635,600 |
|
|
| 340,616 |
|
|
| 8,334 |
|
| 0 |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
| Exhibit Description |
|
|
| 2019 Equity Incentive Plan (As amended through March 2, 2023) | |||
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
| ENANTA PHARMACEUTICALS, INC. |
|
|
|
|
Date: | March 7, 2023 | By: | /s/ Paul J. Mellett |
|
|
| Paul J. Mellett |